Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.

Saved in:
Bibliographic Details
Published inJAMA network open Vol. 5; no. 8; p. e2228997
Main Authors Anderson, Timothy S., O’Donoghue, Ashley, Mechanic, Oren, Dechen, Tenzin, Stevens, Jennifer
Format Journal Article
LanguageEnglish
Published Chicago American Medical Association 01.08.2022
Subjects
Health Policy
Immunotherapy
Monoclonal antibodies
Online Only
Research Letter
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

More Information
Summary:This cross-sectional study uses time-series data to evaluate the administration of bamlanivimab-etesevimab and casirivimab-imdevimab monoclonal antibody treatments for SARS-CoV-2 infection after the US Food and Drug Administration deauthorized their use in early 2022.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2022.28997